Morgan Stanley Finch Therapeutics Group, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.34 - $0.56 $31 - $52	-94 Reduced 11.69%	710 $0
Q4 2022 Feb 14, 2023	SELL	$0.36 - $56.4 $6 - $1,071	-19 Reduced 2.31%	804 $0
Q3 2022 Nov 14, 2022	SELL	$1.75 - $51.3 $46,868 - $1.37 Million	-26,782 Reduced 97.02%	823 $1,000
Q2 2022 Oct 27, 2022	BUY	$1.91 - $5.11 $3,499 - $9,361	1,832 Added 7.11%	27,605 $78,000
Q2 2022 Aug 15, 2022	BUY	$1.91 - $5.11 $3,499 - $9,361	1,832 Added 7.11%	27,605 $78,000
Q1 2022 Oct 27, 2022	SELL	$5.02 - $10.47 $9,196 - $19,181	-1,832 Reduced 6.64%	25,773 $129,000
Q1 2022 May 13, 2022	SELL	$5.02 - $10.47 $8,222 - $17,149	-1,638 Reduced 5.98%	25,773 $129,000
Q4 2021 Feb 14, 2022	BUY	$8.95 - $16.88 $77,166 - $145,539	8,622 Added 45.89%	27,411 $273,000
Q3 2021 Nov 15, 2021	BUY	$12.2 - $16.75 $229,225 - $314,715	18,789 New	18,789 $244,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $525M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.